CSIMarket Company Name, Ticker, Customers, else..
 
Cba Florida Inc   (CBAI)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 1,272
 Employees 2
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Cba Florida Inc
CBA Florida, Inc. (CBAI) is a company based in Florida that specializes in providing private cord blood and cord tissue stem cell services. The company, previously known as Cord Blood America, Inc., was incorporated in October 1999. CBAI operates through its wholly-owned subsidiaries, including CBA Partners, Inc., CBA Companies Inc., CBA Sub Ltd., CBA Properties, Inc., and Career Channel, Inc. (formerly known as Rainmakers International).

CBAI and its subsidiaries, collectively referred to as Cord, were involved in the procurement and preservation of cord blood and cord tissue stem cells for future medical use. Additionally, they engaged in the procurement of birth tissue for organizations involved in transplantation and/or research of therapeutic products.

CBA Properties, Inc. was established to hold corporate trademarks and other intellectual property. The company's business activities were primarily focused on the stem cell and birth tissue industry, catering to the needs of individuals and organizations seeking specialized medical services.




   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Maxcyte Inc

The Top-line plunged at MXCT in the October to December 31 2024 three months

For the fiscal period closing December 31 2024 MXCT Diminishing Returns have swelled of $-0.10 per share compare to $-0.05 a year before and EPS improved from $-0.11 per share from the prior reporting season. The revenue faded by -44.512 % to $8.69 million from $15.66 million in the corresponding reporting season a year before and sequentially revenue grew by 6.467 % from $8.16 million.

Exagen Inc

The company announced a reasonably quiet period, in the financial three months ending December 31 2024

XGN cut its deficit in spite of fading revenus in the fourth quarter of 2024, Revenue sunk by -4.642 % to $13.13 million and shortfall per share decreased to $-0.20 compared to $-0.30 eps achieved in the reporting season a year prior. In contrast to the the Medical Laboratories company's scenario the on averageMedical Laboratories industry, posted a revenue 6.36% growth from the fourth quarter of 2023 in the fourth quarter of 2024.

Fortrea Holdings Inc

Critical fiscal period for the company during the financial time-frame closing Dec 31 2024

FTRE reported disastrous Dec 31 2024 report, where Revenue faded by -54.729 % to $697.00 million and net deficit per share has expanded to $-0.66, from the similar quarter a year before. The remainder ofMedical Laboratories sector, posted a top-line improvement in the fourth quarter of 2024.

Biodesix Inc

Robust 39.276% Top-line rise at the company during the October to December 31 2024 three months

For the financial time-frame ending December 31 2024 company decreased a loss per share of $-0.04 per share compare to $-0.07 a year ago and Income per Share improved from $-0.07 per share from the previous financial reporting period. The revenue jumped by 39.276 % to $20.43 million from $14.67 million in the comparable financial reporting period a year ago and sequentially revenue advanced by 12.55 % from $18.15 million. Biodesix Inc s' revenue, surge in the fourth quarter of 2024 correlates favorably to its Medical Laboratories sector contemporaries, which made on average 11.90 % business improvement during the matching time thus far.

Viridian Therapeutics Inc

Lackluster revenue at VRDN all along the fourth quarter of 2024

For the most recent fiscal period VRDN decreased a loss per share of $-0.77 per share compare to $-1.12 a year prior and EPS improved from $-1.15 per share from the previous financial reporting period. The revenue remained unchanged by 0 % to $0.07 million from $0.07 million in the corresponding financial reporting period a year prior and sequentially revenue fell by -16.279 % from $0.09 million.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com